These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35134813)

  • 1. Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays.
    Shurrab FM; Al-Sadeq DW; Amanullah FH; Al-Absi ES; Qotba H; Yassine HM; Abu-Raddad LJ; Nasrallah GK
    Intervirology; 2022; 65(4):224-229. PubMed ID: 35134813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Arbovirus Antibodies Cross-React With Severe Acute Respiratory Syndrome Coronavirus 2.
    Hunsawong T; Buddhari D; Rungrojcharoenkit K; Suthangkornkul R; Mongkolsirichaikul D; Lohachanakul J; Tayong K; Sirikajornpan K; Rodpradit P; Poolpanichupatam Y; Klungthong C; Utennam D; Kaewhiran S; Cotrone TS; Fernandez S; Jones AR
    Microbiol Spectr; 2022 Dec; 10(6):e0263922. PubMed ID: 36445096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19.
    Chiereghin A; Zagari RM; Galli S; Moroni A; Gabrielli L; Venturoli S; Bon I; Rossini G; Saracino IM; Pavoni M; Lafratta S; Deni A; Felici S; Borghi M; Guerra L; Raumer L; Lodi V; Viale P; Attard L; Lazzarotto T;
    Front Public Health; 2020; 8():620222. PubMed ID: 33681115
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of Serologic Cross-Reactivity Between Dengue Virus and SARS-CoV-2 in Patients with Acute Febrile Illness - United States and Puerto Rico, April 2020-March 2021.
    Munoz-Jordan J; Cardona J; Beltrán M; Colón C; Schiffer J; Stewart-Clark E; Zellner B; Semenova V; Li Y; Jia LT; Maniatis P; Pawloski L; Adams L; Paz-Bailey G; Rivera-Amill V; Medina F
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):375-377. PubMed ID: 35271558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoprotein-based ELISA for detection of SARS-COV-2 IgG antibodies: Could an old assay be suitable for serodiagnosis of the new coronavirus?
    Tozetto-Mendoza TR; Kanunfre KA; Vilas-Boas LS; Sanchez Espinoza EP; Paião HGO; Rocha MC; de Paula AV; de Oliveira MS; Zampelli DB; Vieira JM; Buss L; Costa SF; Sabino EC; Witkin SS; Okay TS; Mendes-Correa MC
    J Virol Methods; 2021 Apr; 290():114064. PubMed ID: 33453299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for Enhanced Detection of SARS-CoV-2 Specific Nucleocapsid and Receptor Binding Domain IgG.
    Sil BK; Jamiruddin MR; Haq MA; Khondoker MU; Jahan N; Khandker SS; Ali T; Oishee MJ; Kaitsuka T; Mie M; Tomizawa K; Kobatake E; Haque M; Adnan N
    Int J Nanomedicine; 2021; 16():4739-4753. PubMed ID: 34267520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis.
    Cheng YL; Chao CH; Lai YC; Hsieh KH; Wang JR; Wan SW; Huang HJ; Chuang YC; Chuang WJ; Yeh TM
    Front Immunol; 2022; 13():941923. PubMed ID: 36045680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study.
    Horn MP; Jonsdottir HR; Brigger D; Damonti L; Suter-Riniker F; Endrich O; Froehlich TK; Fiedler M; Largiadèr CR; Marschall J; Weber B; Eggel A; Nagler M
    Allergy; 2022 Jul; 77(7):2090-2103. PubMed ID: 34986501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance characteristics of five SARS-CoV-2 serological assays: Clinical utility in health-care workers.
    Heffernan E; Kennedy L; Hannan MM; Ramlaul N; Denieffe S; Courtney G; Watt A; Hurley J; Lynch M; Fitzgibbon M
    Ann Clin Biochem; 2021 Sep; 58(5):496-504. PubMed ID: 33845592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
    Infantino M; Manfredi M; Grossi V; Lari B; Fabbri S; Benucci M; Fortini A; Damiani A; Mobilia EM; Panciroli M; Pancani S; Pesce G
    J Med Virol; 2021 Mar; 93(3):1436-1442. PubMed ID: 32790181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
    Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
    Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
    Tré-Hardy M; Wilmet A; Beukinga I; Favresse J; Dogné JM; Douxfils J; Blairon L
    J Med Virol; 2021 Feb; 93(2):803-811. PubMed ID: 32667733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses.
    Lustig Y; Keler S; Kolodny R; Ben-Tal N; Atias-Varon D; Shlush E; Gerlic M; Munitz A; Doolman R; Asraf K; Shlush LI; Vivante A
    Clin Infect Dis; 2021 Oct; 73(7):e2444-e2449. PubMed ID: 32797228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fcγ-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera.
    Deschermeier C; Ehmen C; von Possel R; Murawski C; Rushton B; Amuasi J; Sarpong N; Maiga-Ascofaré O; Rakotozandrindrainy R; Asogun D; Ighodalo Y; Oestereich L; Duraffour S; Pahlmann M; Emmerich P
    J Clin Microbiol; 2022 Jun; 60(6):e0007522. PubMed ID: 35574677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological tests reveal significant cross-reactive human antibody responses to Zika and Dengue viruses in the Mexican population.
    Zaidi MB; Cedillo-Barron L; González Y Almeida ME; Garcia-Cordero J; Campos FD; Namorado-Tonix K; Perez F
    Acta Trop; 2020 Jan; 201():105201. PubMed ID: 31562846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low risk of serological cross-reactivity between dengue and COVID-19.
    Spinicci M; Bartoloni A; Mantella A; Zammarchi L; Rossolini GM; Antonelli A
    Mem Inst Oswaldo Cruz; 2020; 115():e200225. PubMed ID: 32813814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).
    Nicol T; Lefeuvre C; Serri O; Pivert A; Joubaud F; Dubée V; Kouatchet A; Ducancelle A; Lunel-Fabiani F; Le Guillou-Guillemette H
    J Clin Virol; 2020 Aug; 129():104511. PubMed ID: 32593133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].
    Ergünay K; Saygan MB; Aydoğan S; Litzba N; Niedrig M; Pınar A; Us D
    Mikrobiyol Bul; 2010 Jul; 44(3):415-24. PubMed ID: 21063991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test.
    Nath H; Mallick A; Roy S; Kayal T; Ranjan S; Sengupta S; Sukla S; Biswas S
    Int J Infect Dis; 2022 Sep; 122():576-584. PubMed ID: 35811081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.